Ratings Lepu Biopharma Co., Ltd.

Equities

2157

CNE100004SM4

Market Closed - Hong Kong S.E. Other stock markets 04:08:17 2024-05-17 am EDT			5-day change	1st Jan Change
4.95 ^HKD	-6.07%		-15.09%	+17.58%

May. 17	Lepu Biopharma Targets Up to HK$230 MIllion in Share Placement; Shares Fall 5%	MT
Apr. 12	Keymed Biosciences Advances Solid Tumors Drug With First Patient Study	MT

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
Based on current prices, the company has particularly high valuation levels.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
Over the past four months, analysts' average price target has been revised downwards significantly.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
LEPU BIOPHARMA CO., LTD.	+17.58%	1.05B	-
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	115B	B+
REGENERON PHARMACEUTICALS, INC.	+11.84%	106B	B+
ARGENX SE	-1.05%	21.96B	B
BIONTECH SE	-14.15%	21.84B	B+
GENMAB A/S	-5.29%	19.21B	A-
BEIGENE, LTD.	-4.16%	18.08B	B
WUXI APPTEC CO., LTD.	-38.29%	17.71B	A-
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.32B	C+
SAREPTA THERAPEUTICS, INC.	+36.24%	12.42B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes